Last reviewed · How we verify
ABSK043 oral capsule
ABSK043 oral capsule is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | ABSK043 oral capsule |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Clinical Study of ABSK061 and ABSK043 (PHASE2)
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABSK043 oral capsule CI brief — competitive landscape report
- ABSK043 oral capsule updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI
Frequently asked questions about ABSK043 oral capsule
What is ABSK043 oral capsule?
ABSK043 oral capsule is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd.
Who makes ABSK043 oral capsule?
ABSK043 oral capsule is developed by Abbisko Therapeutics Co, Ltd (see full Abbisko Therapeutics Co, Ltd pipeline at /company/abbisko-therapeutics-co-ltd).
What development phase is ABSK043 oral capsule in?
ABSK043 oral capsule is in Phase 1.
Related
- Manufacturer: Abbisko Therapeutics Co, Ltd — full pipeline
- Compare: ABSK043 oral capsule vs similar drugs
- Pricing: ABSK043 oral capsule cost, discount & access